On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. As outlined in Company Announcement no. 48 of 14 August 2026, the programme was extended with up to DKK 170 million, increasing the total amount of which Schouw & Co. will acquire shares to up to DKK 410 million.

The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).

Trading day No. of
shares
Average
price
Amount
DKK
   
Accumulated until 23 October 2026 557,541 722.93 403,065,580    
Monday, 26 October 2026 750 847.00 635,250    
Tuesday, 27 October 2026 830 831.08 689,800    
Wednesday, 28 October 2026 830 834.00 692,220    
Thursday, 29 October 2026 830 835.92 693,814    
Friday, 30 October 2026 830 829.00 688,070    
In the period 26 October 2026 – 30 October 2026 4,070 835.17 3,399,154    
Accumulated until 30 October 2026 561,611 723.75 406,464,734    
           
Following the above transactions, Schouw & Co. holds a total of 2,859,404 treasury shares corresponding to 11.44% of the total share capital of 25,000,000 shares.    
   

Aktieselskabet Schouw & Co.

Jørgen Dencker Wisborg, Chairman
Jens Bjerg Sørensen, President, telephone number +45 86 11 22 22

Attachments

WOODBURY, NY, Nov. 02, 2026 (GLOBE NEWSWIRE) — Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its third quarter 2026 financial results on Thursday, November 5, 2026. Research Frontiers will also host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2026 to discuss its third quarter 2026 financial and operating results, as well as recent developments.

About Research Frontiers

Research Frontiers (Nasdaq: REFR) is a publicly traded technology company and the developer of patented SPD-Smart light-control film technology which allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically. Research Frontiers has licensed its smart glass technology to numerous companies that include well known chemical, material science and glass companies. Products using Research Frontiers’ smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings. For more information, please visit our website at www.SmartGlass.com, and on Facebook, Twitter, LinkedIn and YouTube.

Note: From time to time Research Frontiers may issue forward-looking statements which involve risks and uncertainties. This press release contains forward-looking statements. Actual results, especially those reliant on activities by third parties, could differ and are not guaranteed. Any forward-looking statements should be considered accordingly. “SPD-Smart” and “SPD-SmartGlass” are trademarks of Research Frontiers Inc.

CONTACT
Joseph M. Harary
President and CEO
Research Frontiers Inc.
 +1-516-364-1902
Info@SmartGlass.com

MIDLAND, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) — Big Digital Energy, Inc. (“We,” “Big Digital” or the “Company”) (Nasdaq: “BGDE”), a developer and operator of next-generation digital infrastructure, today announced that Executive Chairman Josh Kilgore and Chief Executive Officer Phil Stanley will participate in the Cantor Crypto and AI Infrastructure Conference, taking place November 10–12, 2026, in Miami, Florida. Mr. Kilgore will also participate in a panel discussion on Thursday, November 12, at 11:20 a.m. ET. Interested investors should contact their Cantor representatives to schedule a meeting during the conference.

Cantor Crypto and AI Infrastructure Conference

  • Date: November 10-12, 2026
  • Location: Miami, FL
  • Panel Discussion with Executive Chairman Josh Kilgore: November 12, 2026, at 11:20 a.m. ET

About Big Digital Energy, Inc.

Big Digital Energy, Inc. (Nasdaq: “BGDE”) is a U.S.-based technology company that designs, builds, and operates next-generation digital infrastructure platforms. The Company provides services spanning artificial intelligence (“AI”), high-performance computing (“HPC”), digital assets (including Bitcoin mining), and other intensive compute applications. The Company delivers both self-mining operations and colocation/hosting for enterprise customers, with a vertically integrated infrastructure model built for scalability and efficiency.

A core part of the Company’s strategy is identifying and advancing sites positioned to support high-performance compute with the infrastructure required for long-term deployment. With approximately 169 megawatts of energized capacity and additional capacity under development, the Company is positioning itself as a competitive provider of digital infrastructure solutions to support the demand for AI data centers.

CONTACT

Investor Relations: IR@bigdigital.energy
Partnerships: Partnerships@bigdigital.energy
Media and Press: mediarelations@bigdigital.energy
Website: www.bigdigital.energy

MOA establishes framework to assess potential deployment of Roze AI’s fire forecasting system across seven planned data center developments in South Korea

SEONGNAM, South Korea, Nov. 02, 2026 (GLOBE NEWSWIRE) — Roze AI Inc. (Nasdaq: RZAI) (“Roze AI” or the “Company”) today announced that its wholly owned Korean operating subsidiary, Roze AI Korea Co., Ltd., signed a Memorandum of Agreement (“MOA”) with BKB Energy Co., Ltd. on October 20, 2026, to evaluate the technical suitability and feasibility of integrating Roze AI’s proprietary AI fire forecasting system into BKB Energy’s planned AI data center development projects.

Young Jin Cho, Chief Executive Officer of Roze AI, stated, “We see BKB Energy’s planned development of AI data centers across seven locations in South Korea as a significant opportunity to demonstrate the value of our AI fire forecasting system. This MOA provides a framework for working with the relevant parties to determine the scope of technical implementation, design requirements, and commercial terms necessary for a definitive agreement.”

Under the MOA, the parties will evaluate how Roze AI Korea’s technologies may be applied to the planned facilities and incorporated into project plans and designs. Discussions will cover technical specifications, installation integration, and operational and maintenance arrangements, with the objective of determining whether the system should be deployed and how it may be adapted to the requirements of each facility. Requirements relating to legally mandated fire protection systems will be addressed separately in accordance with applicable laws and regulations.

According to BKB Energy, its AI data center development projects identified in the MOA are planned to proceed sequentially. The currently planned project sites are as follows:

  1. Hannam University Defense AX Center, Daejeon – 240 MW (Phase 1: 40 MW)
  2. Yeongwol, Gangwon Province (EMP-protected facility) – 260 MW
  3. Samcheok, Gangwon Province – 800 MW
  4. Okgye, Gangwon Province – 200 MW
  5. Pocheon, Gyeonggi Province – 120 MW
  6. Pyeongtaek, Gyeonggi Province – 200 MW
  7. Hongseong, South Chungcheong Province – 80 MW

The MOA establishes a non-binding framework for cooperation between the parties. If definitive agreements are subsequently executed, the final scope, pricing, and commercial terms for the AI fire forecasting system and associated components to be supplied by Roze AI Korea—including sensors, monitoring, alerting, and software—will be determined based on project feasibility assessments, the authority to enter into contracts, required approvals, and the execution of separate definitive agreements. The MOA does not constitute a binding purchase order, revenue guarantee or capital commitment by Roze AI.

Under the MOA, the parties have established an initial target period of 60 days from the execution date for technical review and discussions of commercial terms. This period is not a deadline for executing a definitive agreement and may be adjusted in writing depending on the progress of discussions. The MOA will remain in effect until October 20, 2027, unless terminated earlier or extended in writing.

About Roze AI Inc.

Roze AI is a Canadian Physical AI technology company operating through its wholly owned subsidiary, Roze AI Korea Co., Ltd., in Seongnam, South Korea.

The Company’s Disaster AI Platform (DAP) analyzes sensor and facility data using AI and digital twin technology to generate a Fire Risk Index that supports fire risk assessment, monitoring and early warning.

Through Roze AI Korea Co., Ltd., the Company develops and provides Fire 4Cast, Disaster AI Platform (DAP) and other solutions for buildings, facilities and urban infrastructure.

For more information, please visit www.rozeai.com.

Investor Relations / Media Relations

Roze AI Inc.
Email: ir@rozeai.com

Investor Relations – North America

Jack Perkins
KCSA Strategic Communications
Email: rozeai@kcsa.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements under applicable U.S. federal securities laws, including the Private Securities Litigation Reform Act of 1995. These include the potential business scope under the MOA; its possible progression to a definitive agreement; and technology application. These statements reflect current expectations, estimates and assumptions and are subject to risks and uncertainties.

Actual results may differ materially due to feasibility findings; contracting authority and third-party decisions; permits and approvals; project financing; design, scope, price or schedule changes; failure to enter definitive agreements; termination, postponement or cancellation; technology requirements; customer performance and revenue recognition; regulatory and market conditions; and risks described in the Company’s SEC filings. Readers should not place undue reliance on these statements, which speak only as of this release. The Company undertakes no obligation to update them except as required by applicable law.

PITTSBURGH, Nov. 02, 2026 (GLOBE NEWSWIRE) — L.B. Foster Company (NASDAQ: FSTR), a global technology solutions provider of products and services for the Rail and Infrastructure markets, announced today that its Board of Directors has approved certain changes among its executive officers effective November 1, 2026 (the Effective Date).

Ms. Sara Rolli currently serves as the Company’s Senior Vice President – Operational Administration and is appointed Senior Vice President – Steel Products and Operational Excellence on the Effective Date, and will continue to report to Bill Thalman, Executive Vice President and Chief Operating Officer. In addition to her current responsibilities overseeing the Company’s Quality, EHS and Continuous Improvement functions, Ms. Rolli will now have operational oversight of the Steel Products business unit within the Company’s Infrastructure segment.  Ms. Rolli, age 45, has served as SVP – Operational Administration since 2025, served as VP – Operational Administration from 2023 – 2025, and served as the Company’s Director of Quality from 2019 – 2023. She was also Senior Quality Manager from 2015 – 2017 and Site Quality Manager from 2013 – 2015. Prior to joining the Company, Ms. Rolli was employed by Kennametal, Inc. and Praxair. Ms. Rolli holds Bachelor of Science and Master of Arts degrees from Waynesburg University.

In connection with Ms. Rolli’s change in responsibilities, Mr. Robert (Bob) Ness, currently serving as Senior Vice President – Infrastructure segment, is appointed Senior Vice President – Precast Concrete Products on the Effective Date, also continuing to report to Mr. Thalman. He will cease to serve as SVP – Infrastructure on the Effective Date and will lead the Company’s Precast Concrete Products business unit.

Mr. Thalman commented, “We’re pleased to recognize Sara with this important change to her responsibilities. She’s been a valued leader in our organization for over a decade, establishing rigor and sustainability in our Quality, Lean and EHS business processes. This additional assignment overseeing the Steel Products business unit is the next step in her career progression and adds to our operational bench strength. The change also provides Bob with additional bandwidth to focus on our growth initiatives for the Precast Concrete business unit, which is a critical growth platform within our strategic playbook. I congratulate Sara on this well-deserved recognition and look forward to the contributions both Sara and Bob will make in the future.”

Forward-Looking Statements

This release may contain “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements provide management’s current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements. Forward-looking statements in this earnings release are based on management’s current expectations and assumptions about future events that involve inherent risks and uncertainties and may concern, among other things, the Company’s expectations relating to our strategy, goals, projections, valuations and impairments, and plans regarding our financial position, liquidity, capital resources, results of operations and decisions regarding our strategic growth initiatives, market position, and product development. While the Company considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control. The Company cautions readers that various factors could cause the actual results of the Company to differ materially from those indicated by forward-looking statements. Accordingly, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Among the factors that could cause the actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to: adverse economic conditions in the markets we serve, including recession, the volatility in the prices for oil and gas, tariffs, duties or trade wars, inflation, rising labor costs, project delays, and budget shortfalls, or otherwise; the disruption of government funding programs as a result of potential periodic government shutdowns; volatility in the global capital markets, including interest rate fluctuations, which could adversely affect our ability to access the capital markets on terms that are favorable to us; restrictions on our ability to draw on our credit agreement, including as a result of any future inability to comply with restrictive covenants contained therein; a decrease in freight or transit rail traffic; environmental matters and the impact of environmental regulations, including any costs associated with any remediation and monitoring of such matters; the risk of doing business in international markets, including compliance with anti-corruption and bribery laws, foreign currency fluctuations and inflation, global shipping disruptions, the imposition of increased or new tariffs, and trade restrictions or embargoes, or uncertainties relating to the imposition and enforcement of tariffs; our ability to timely effectuate our strategy, including cost reduction initiatives, and our ability to effectively integrate acquired businesses or to divest businesses, and to realize anticipated synergies and benefits; costs of and impacts associated with shareholder activism; the timeliness, cost, and availability of materials from our major suppliers, as well as the impact on our access to supplies of customer preferences as to the origin of such supplies, such as customers’ concerns about conflict minerals; labor disputes; emerging technologies, including those related to or arising from artificial intelligence, and resultant risks to our business and operations; cybersecurity risks such as data security breaches, malware, ransomware, “hacking,” and identity theft, either with respect to our systems or those of third parties on whom we rely, which could disrupt our business and may result in misuse or misappropriation of confidential or proprietary information, and could result in the disruption or damage to our systems, increased costs and losses, or an adverse effect to our reputation, business or financial condition; the continuing effectiveness of our ongoing implementation of an enterprise resource planning system; changes in current accounting estimates and their ultimate outcomes; the adequacy of internal and external sources of funds to meet financing needs, including our ability to negotiate any additional necessary amendments to our credit agreement or the terms of any new credit agreement, the Company’s ability to manage its working capital requirements and indebtedness; domestic and international taxes, including estimates that may impact taxes; domestic and foreign government regulations, including tariffs; our ability to maintain effective internal controls over financial reporting and disclosure controls and procedures; any change in policy or other change due to the results of the UK’s parliamentary elections and the U.S. presidential and congressional elections that could affect UK or US business conditions; other geopolitical conditions, including the ongoing conflicts between Russia and Ukraine, conflicts in the Middle East, and increasing tensions between China and Taiwan; a lack of, freezing of, or delay in state or federal funding for infrastructure projects; an increase in manufacturing or material costs, including volatility in steel prices, oil prices, and wage inflation; the loss of future revenues from current customers; any future global health crises, and the related social, regulatory, and economic impacts and the response thereto by the Company, our employees, our customers, and national, state, or local governments, including any governmental travel restrictions; and risks inherent in litigation and the outcome of litigation and product warranty claims. Should one or more of these risks or uncertainties materialize, or should the assumptions underlying the forward-looking statements prove incorrect, actual outcomes could vary materially from those indicated. Significant risks and uncertainties that may affect the operations, performance, and results of the Company’s business and forward-looking statements include, but are not limited to, those set forth under Item 1A, “Risk Factors,” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, or as updated and/or amended by our other current or periodic filings with the Securities and Exchange Commission.

The forward-looking statements in this release are made as of the date of this release and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by the federal securities laws.

Marketing and Communications:

Meredith Faust
412-928-3400, and follow the prompts
lbfmarketing@lbfoster.com

L.B. Foster Company
415 Holiday Drive
Suite 100
Pittsburgh, PA 15220

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that company management will participate in fireside chats at upcoming investor conferences:

  • Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9th at 10:30 a.m. ET
  • Stifel 2026 Healthcare Conference on Thursday, November 12th at 2:00 p.m. ET
  • UBS Global Biopharma Conference on Tuesday, November 17th at 3:40 a.m. ET / 8:40 a.m. GMT
  • Jefferies London Global Healthcare Conference on Wednesday, November 18th at 6:30 a.m. ET / 11:30 a.m. GMT

Disc management will be participating in investor meetings during the above conferences, as well as during the Truist BioPharma Symposium in New York on Thursday, November 12.

Live webcasts of the fireside chats will be available through the investor relations section of the Company’s website at ir.discmedicine.com and an archived replay will be available after each event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Kevin Lui
Precision AQ
kevin.lui@precisionaq.com

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report third quarter 2026 financial results and business updates before the market opens on Monday, November 9, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.

About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Tim Palmer
Tim.Palmer@bicara.com

Pilot program will evaluate autonomous robotic support for linen transport and event operations

AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — via IBN – TechForce Robotics, Inc. (“TechForce”), a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), today announced a 60-day pilot program at Fairmont Austin focused on autonomous robotic support across select hotel operations.

During the pilot, TechForce robotic systems will autonomously transport soiled linens and pool towels across select areas of the property. The robots will be configured around the hotel’s existing workflows, with the goal of reducing manual transport and heavy lifting for team members.

“This pilot is about showing how autonomous robotics can provide practical support in demanding hospitality environments,” said Ried Floco, president and director of TechForce Robotics. “By taking on repetitive material transport, these systems can allow team members to focus their time and attention on other responsibilities.”

About TechForce Robotics, Inc.

TechForce Robotics, Inc., a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), is a technology company focused on the development and commercialization of robotics and automation solutions. The company develops autonomous robotic systems and integrated software designed to support workforces, improve operational efficiency and automate repetitive tasks across commercial and enterprise environments. TechForce offers flexible deployment options, including a fully managed subscription model (RaaSP) that includes deployment, maintenance and ongoing support.

About Nightfood Holdings, Inc. (OTCQB: NGTF)

Nightfood Holdings Inc., doing business as TechForce Robotics, is an advanced robotics and automation company focused on delivering intelligent, scalable solutions for industrial and commercial applications. The Company integrates robotics, artificial intelligence, software-driven systems and strategic manufacturing capabilities to address evolving operational needs across multiple industries.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Such statements include expectations regarding manufacturing partnerships, production timelines, future revenue, robotics commercialization, customer deployments, corporate initiatives, potential exchange listing and future growth opportunities. These statements involve risks and uncertainties, and actual results may differ materially from those anticipated. Proposed transactions and commercial initiatives remain subject to applicable agreements, approvals, operational requirements and other conditions. The Company undertakes no obligation to update forward-looking statements except as required by law. Investors should review the Company’s filings with the Securities and Exchange Commission for further information regarding risks and uncertainties.

For more information on Nightfood Holdings, Inc. (OTCQB: NGTF), please visit www.nightfoodholdings.com.

Investor Relations, Media Relations and Corporate Communications

Investor Relations
Nightfood Holdings, Inc
www.nightfoodholdings.com

Media Relations
media@nightfoodholdings.com

Corporate Communications
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Adam Steinberg, Mickey Brunton, and Gavin Kolt Strengthen Capital Structure Advisory, GP-Led Secondaries, and Private Capital Markets Capabilities

ST. LOUIS, Nov. 02, 2026 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) (“Stifel”) today announced the recent additions of Adam Steinberg, Mickey Brunton, and Gavin Kolt to senior leadership roles across its Capital Solutions platform. All three are serving as Managing Directors based in New York, and represent important additions to Stifel’s capabilities in capital structure advisory, GP-led secondaries, and private capital markets.

The appointments deepen Stifel’s ability to advise corporate and financial sponsor clients across the full capital structure. Stifel’s Capital Solutions platform integrates its Equity Capital Markets, Leveraged Finance, Private Capital Advisory, and Capital Structure Advisory groups with the firm’s M&A and industry coverage bankers to provide clients with a comprehensive range of financing and strategic advisory solutions.

“Stifel’s Capital Solutions Group has been purpose-built to provide our corporate and sponsor clients the full spectrum of advisory and financing options on a single platform,” said Seth Rubin, Head of Global Equity Capital Markets at Stifel. “Bringing in Adam, Mickey, and Gavin as trusted experts in their markets significantly enhances our ability to drive best outcomes for our clients.”

Adam Steinberg joins as Head of Stifel’s Capital Structure Advisory Group, which advises public and private companies, and their stakeholders, across a full range of balance sheet solutions. Mr. Steinberg brings 25 years of investment banking and asset management experience, advising clients on mergers and acquisitions, financing transactions, restructurings, and other complex capital structure matters across a wide range of industries. Before joining Stifel, Mr. Steinberg was a Managing Director at Moelis & Company. Previously, he was a credit analyst at Lonestar Capital Management, and earlier in his career was a Vice President in the Recapitalization & Restructuring Group at Jefferies.

Mickey Brunton serves as Co-Head of Eaton Partners’ GP-led Secondaries Advisory Group, advising financial sponsors on GP-led secondary transactions and innovative liquidity solutions. Through Eaton Partners, clients benefit from access to Stifel’s broader investment banking platform, including primary fundraising, GP and LP led secondary advisory, direct/co-investment fundraising, and GP strategic capital advisory. Throughout his career, Mr. Brunton has advised on and structured approximately $5 billion in secondary transactions. Prior to joining Eaton Partners, Mr. Brunton was Head of Secondaries at Connaught LLC, and before that, served in Jefferies’ Private Capital Advisory group.

Gavin Kolt is Head of Stifel’s Private Capital Markets Group, advising companies and their sponsors on privately negotiated equity, structured equity, and equity-linked financings for growth, acquisitions, liquidity, and balance sheet optimization. Mr. Kolt brings more than 25 years of private capital markets experience and has advised on and structured transactions totaling more than $60 billion. Most recently, Mr. Kolt was a Managing Director and Head of Equity Private Capital Markets at Baird. Previously, he was a Managing Director at Moelis & Company, a Director at Merrill Lynch, and began his investment banking career at Sheshunoff & Co.

These hires build on Stifel’s continued growth in its investment banking platform, which includes more than 750 professionals worldwide.

Stifel Company Information
Stifel Financial Corp. (NYSE: SF) is a diversified financial services firm providing wealth management, commercial and investment banking, trading, and research services to individuals, institutions, and municipalities. Founded in 1890 and headquartered in St. Louis, Missouri, the firm operates more than 400 offices across the United States and in major global financial centers. As a firm where success meets success, Stifel works closely with retail and institutional clients aiming to transform opportunities into achievement. To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit www.stifel.com/investor-relations/press-releases.

About Eaton Partners
Eaton Partners, a Stifel Company, is one of the world’s largest private capital advisory firms, having raised more than $140 billion across more than 190 highly differentiated alternative investment funds and offerings. Founded in 1983, Eaton advises and raises institutional capital for investment managers across alternative strategies – private equity, private credit, real assets, and real estate in both the primary and secondary markets. Eaton Partners maintains offices and operates throughout North America, Europe, and Asia. Eaton Partners is a division of Stifel, Nicolaus & Company, Incorporated, Member SIPC and NYSE. For more information, please visit https://eaton-partners.com/.

Media Contacts
Neil Shapiro, +1 (212) 271-3447, shapiron@stifel.com
Evan Roesen, +1 (212) 271-3760, roesene@stifel.com

Investor Relations Contact
Joel Jeffrey, +1 (212) 271-3610, investorrelations@stifel.com

SEATTLE and VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that the Compensation Committee of Achieve’s Board of Directors approved stock option grants to purchase an aggregate of 97,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 97,000 shares of its common stock for three new employees.

The stock options have an exercise price equal to the closing price of Achieve’s common stock on the applicable grant date. Each stock option has a four-year vesting period and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment. The remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to the employee’s continued service through each applicable vesting date.

Each RSU award represents the right to receive one share of Achieve’s common stock upon vesting, subject to the recipient’s continued service. The RSUs will vest over four years with 25% of the underlying shares vesting on each anniversary following commencement of employment, subject to the employee’s continued service through each applicable vesting date.

The stock options and RSU awards are subject to the terms and conditions of the 2024 Equity Inducement Plan, as well as the terms and conditions of the stock option agreement or RSU award agreement covering the grants and were made as an inducement material to the individuals entering into employment with Achieve in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Cytisinicline is an investigational compound that binds to nicotinic receptors. It is being developed as an aid to smoking cessation treatment in adults and as an aid to nicotine e-cigarette cessation.

About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing, nature and outcome of cytisinicline clinical development and regulatory review and approval, data results, the timing, nature and success of Achieve’s commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, the performance of Achieve’s third-party manufacturing partners, the successful launch and commercialization of cytisinicline, and statements concerning Achieve Life Sciences’ future plans and prospects. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those described in Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
media@achievelifesciences.com
425-686-1510

Reference
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.